However, despite its critical role in immune‐mediated renal injury, CXCL9 blockade has been shown to impair anti‐tumor immune responses in preclinical models,[22] suggesting that its clinical utility may lie more in renal‐specific immune monitoring rather than therapeutic inhibition in oncology. This evidence concerns the gene CXCL9 and neoplasm.